Patient Brochure

MYLOTARG is a CD33-directed antibody drug conjugate indicated for treatment of1:
  • Newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults
  • Relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older
  • MYLOTARG is a CD33-directed antibody drug conjugate. Once bound to CD33, MYLOTARG is internalized by the tumor cell, resulting in intracellular release and activation of the cytotoxic agent calicheamicin, which induces cell death via double-strand DNA breaks
Newly diagnosed patients1
  • Combination regimen for induction: in patients with newly diagnosed de novo CD33-positive AML, the recommended dose of MYLOTARG is 3 mg/m2 (up to one 4.5-mg vial) on Days 1, 4, and 7, in combination with daunorubicin and cytarabine. For consolidation, the recommended dose of MYLOTARG is a single dose of 3 mg/m2 (up to one 4.5-mg vial) on Day 1 in combination with daunorubicin and cytarabine
  • Single-agent regimen for induction: in patients with newly diagnosed AML, the recommended dose of MYLOTARG is 6 mg/m2 (not limited to one 4.5-mg vial) as a single agent on Day 1 and 3 mg/m2 (not limited to one 4.5-mg vial) on Day 8. For patients without evidence of disease progression following induction, up to 8 continuation courses of MYLOTARG 2 mg/m2 (not limited to one 4.5-mg vial) on Day 1 every 4 weeks are allowed
Relapsed/refractory patients1
  • For relapsed/refractory CD33-positive AML, the recommended dose of MYLOTARG is 3 mg/m2 (up to one 4.5-mg vial) as a single agent on Days 1, 4, and 7
Download the Patient Brochure for more information.
REFERENCE
1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.